Richard Wu on a phase 1 trial of a broadly neutralising antibody for HIV

In HIV prevention and treatment, broadly neutralising antibodies have so far failed failed to deliver on their potential; could N6LS buck the trend? Richard Wu talks about a phase 1 study with some promising results. Read the full article: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00041-4/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanhiv Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv